Clinical trial · Observational
Prevalence of Anticipatory Nausea and Vomiting in Cancer Patients Exposed to Highly Emetogenic Chemotherapy
NCT04785495CI-TRIAL-00050532unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Chemotherapy induced nausea and vomiting are common adverse events related to oncologic treatments. It can have deleterious effect on patients' quality of life and could lead to dose reductions and/or discontinuation of treatment. This study aims to quantify the prevalence of nausea and vomiting induced by highly emetogenic chemotherapy in patients who had adequate antiemetic prophylaxis, also to describe the epidemiologic profile and identify predisposing factors.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy-induced Nausea and Vomiting | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Quality-of-life assessment | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cancer Patients Exposed to Highly Emetogenic Chemotherapy
- description
- Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis.
- interventionNames
- Other: Quality-of-life assessment
Primary outcomes (1)
- measure
- Prevalence of anticipatory nausea and vomiting in cancer patients undergoing highly emetogenic chemotherapy regimen
- timeFrame
- Baseline to 6 days after chemotherapy
- description
- The prevalence of nausea and vomiting will be determined by the percentage of patients reporting the presence of a symptom at the assessment time point. Participants are asked to report any episodes of nausea and vomiting before (baseline) and up to 6 days after receiving chemotherapy. This result is measured during the first and second cycles of chemotherapy for each patient.
Secondary outcomes (2)
- measure
- Patient's daily diary
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histological confirmation of cancer; * Patients who will start chemotherapy with a high-grade emetogenic scheme and who have received adequate antiemetic prophylaxis; * No previous cancer treatment for the current diagnosis (excluding surgery); Exclusion Criteria: * Patients who have an inability to answer the questionnaire, due to lack of discernment to answer the questions reliably; * Patients who report vomiting during the 24 hours prior to the first cycle of chemotherapy treatment; * Patients who have a disease or condition that could cause emesis (ie, metastasis in the central nervous system, gastrointestinal obstruction or metabolic and electrolyte imbalances); * Patients using opioids or illicit drugs; * Alcoholism;
References
Publications (0)
Data not yet available
No reference posted for this study.